Cargando…
The future risk of primary biliary cholangitis (PBC) is low among patients with incidental anti‐mitochondrial antibodies but without baseline PBC
Anti‐mitochondrial autoantibodies (AMAs) are highly specific for the diagnosis of primary biliary cholangitis (PBC) but are also occasionally found in other diseases. In the present study, we evaluated the incidence of and predictors for PBC development in AMA‐positive patients with other liver or n...
Autores principales: | Duan, Weijia, Chen, Sha, Li, Shuxiang, Lv, Tingting, Li, Buer, Wang, Xiaoming, Wang, Yu, Zhao, Xinyan, Ma, Hong, Ou, Xiaojuan, You, Hong, Jia, Jidong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9592779/ https://www.ncbi.nlm.nih.gov/pubmed/35998274 http://dx.doi.org/10.1002/hep4.2067 |
Ejemplares similares
-
Changing Nomenclature for PBC: From ‘Cirrhosis' to ‘Cholangitis'
por: Beuers, Ulrich, et al.
Publicado: (2015) -
Impact of Microbes on the Pathogenesis of Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis (PSC)
por: Mattner, Jochen
Publicado: (2016) -
The British Society of Gastroenterology/UK-PBC primary biliary cholangitis treatment and management guidelines
por: Hirschfield, Gideon M, et al.
Publicado: (2018) -
Emerging therapies for PBC
por: Chascsa, David Maxwell Hunter, et al.
Publicado: (2020) -
Measurement properties of the PBC-40 and PBC-27: a Dutch validation study
por: de Veer, Rozanne C, et al.
Publicado: (2021)